{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:28Z","timestamp":1793330788179,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fibroblast growth factor receptor (\n                    <jats:italic>FGFR<\/jats:italic>\n                    ) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1\u2013FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of\n                    <jats:italic>FGFR-<\/jats:italic>\n                    altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions\/rearrangements,\n                    <jats:italic>n<\/jats:italic>\n                    = 49) and B (activating non-kinase domain mutations,\n                    <jats:italic>n<\/jats:italic>\n                    = 32). Secondary end points were progression-free survival, duration of response and overall survival in cohorts A and B, and safety. Exploratory end points included ORR of cohort C (kinase domain mutations, potentially pathogenic variants of unknown significance,\n                    <jats:italic>n<\/jats:italic>\n                    = 26) and analysis of co-alterations associated with resistance and response. ORRs for cohorts A, B and C were 26.5% (13\/49), 9.4% (3\/32) and 3.8% (1\/26), respectively. Tumors with no approved FGFR inhibitors or those with alterations not previously confirmed to be sensitive to FGFR inhibition had objective responses. In cohorts A and B, the median progression-free survival was 4.5 and 3.7 months, median duration of response was 7.8 and 6.9 months and median overall survival was 17.5 and 11.4 months, respectively. Safety was consistent with previous reports. The most common any-grade treatment-emergent adverse events were hyperphosphatemia (84%) and stomatitis (53%).\n                    <jats:italic>TP53<\/jats:italic>\n                    co-mutations were associated with lack of response and\n                    <jats:italic>BAP1<\/jats:italic>\n                    alterations with higher response rates.\n                    <jats:italic>FGFR1<\/jats:italic>\n                    \u2013\n                    <jats:italic>FGFR3<\/jats:italic>\n                    gatekeeper and molecular brake mutations led to acquired resistance. New therapeutic areas for FGFR inhibition and drug failure mechanisms were identified across tumor types. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03822117\">NCT03822117<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-024-02934-7","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T06:02:12Z","timestamp":1714975332000},"page":"1645-1654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Pemigatinib in previously treated solid tumors with activating FGFR1\u2013FGFR3 alterations: phase 2 FIGHT-207 basket trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"Jordi","family":"Rod\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9560-1092","authenticated-orcid":false,"given":"Silvia","family":"Damian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Furqan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-3601","authenticated-orcid":false,"given":"Jes\u00fas","family":"Garc\u00eda-Donas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-5351","authenticated-orcid":false,"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-2630","authenticated-orcid":false,"given":"Iben","family":"Spanggaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7949","authenticated-orcid":false,"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Gilmartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1381-0275","authenticated-orcid":false,"given":"Michael","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-6221","authenticated-orcid":false,"given":"Lipika","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"2934_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina, I. S. & Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17, 318\u2013332 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2934_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100641","volume":"7","author":"K Murugesan","year":"2022","unstructured":"Murugesan, K. et al. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. ESMO Open 7, 100641 (2022).","journal-title":"ESMO Open"},{"key":"2934_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten, T. et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259\u2013267 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2934_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. FGF\/FGFR signaling in health and disease. Signal Transduct. Target Ther. 5, 181 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2934_CR5","unstructured":"Incyte. PEMAZYRE (pemigatinib). Full prescribing information. (2022)."},{"key":"2934_CR6","unstructured":"Janssen Biotech. BALVERSA (erdafitinib). Full prescribing information. (2022)."},{"key":"2934_CR7","unstructured":"Taiho Oncology. LYTGOBI (futibatinib). Full prescribing information. (2023)."},{"key":"2934_CR8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant, S. et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 24, 925\u2013935 (2023).","journal-title":"Lancet Oncol."},{"key":"2934_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann. Oncol. 33, 522\u2013533 (2022).","journal-title":"Ann. Oncol."},{"key":"2934_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 12, 402\u2013415 (2022).","journal-title":"Cancer Discov."},{"key":"2934_CR11","doi-asserted-by":"publisher","first-page":"TPS4165","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4165","volume":"39","author":"AM Schram","year":"2021","unstructured":"Schram, A. M. et al. First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors. J. Clin. Oncol. 39, TPS4165\u2013TPS4165 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2934_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"L Nogova","year":"2017","unstructured":"Nogova, L. et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J. Clin. Oncol. 35, 157\u2013165 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2934_CR13","doi-asserted-by":"publisher","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","volume":"15","author":"PCC Liu","year":"2020","unstructured":"Liu, P. C. C. et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS ONE 15, e0231877 (2020).","journal-title":"PLoS ONE"},{"key":"2934_CR14","doi-asserted-by":"crossref","unstructured":"Sootome, H. et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 80, 4986\u20134997 (2020).","DOI":"10.1158\/0008-5472.CAN-19-2568"},{"key":"2934_CR15","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/1535-7163.MCT-16-0518","volume":"16","author":"JD Karkera","year":"2017","unstructured":"Karkera, J. D. et al. Oncogenic characterization and pharmacologic sensitivity of activating fibroblast growth factor receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib. Mol. Cancer Ther. 16, 1717\u20131726 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"2934_CR16","doi-asserted-by":"crossref","unstructured":"Subbiah, V. et al. RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer Discov. 13, 2012\u20132031 (2023).","DOI":"10.1158\/2159-8290.CD-23-0475"},{"key":"2934_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","volume":"608","author":"D Zingg","year":"2022","unstructured":"Zingg, D. et al. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608, 609\u2013617 (2022).","journal-title":"Nature"},{"key":"2934_CR18","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.3390\/ijms21186856","volume":"21","author":"A De Luca","year":"2020","unstructured":"De Luca, A. et al. FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention. Int. J. Mol. Sci. 21, 6856 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2934_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00204-0","volume":"5","author":"IT Nakamura","year":"2021","unstructured":"Nakamura, I. T. et al. Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. NPJ Precis. Oncol. 5, 66 (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"2934_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","volume":"27","author":"H Chen","year":"2007","unstructured":"Chen, H. et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 27, 717\u2013730 (2007).","journal-title":"Mol. Cell"},{"key":"2934_CR21","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","volume":"13","author":"F Facchinetti","year":"2023","unstructured":"Facchinetti, F. et al. Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer. Cancer Discov. 13, 1998\u20132011 (2023).","journal-title":"Cancer Discov."},{"key":"2934_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal, L. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252\u2013263 (2017).","journal-title":"Cancer Discov."},{"key":"2934_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s42004-022-00718-z","volume":"5","author":"Q Lin","year":"2022","unstructured":"Lin, Q. et al. Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. Commun. Chem. 5, 100 (2022).","journal-title":"Commun. Chem."},{"key":"2934_CR24","doi-asserted-by":"crossref","unstructured":"Wu, Q. et al. Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma. Clin. Cancer Res. 30, 198\u2013208 (2023).","DOI":"10.1158\/1078-0432.CCR-23-1317"},{"key":"2934_CR25","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","volume":"8","author":"SK Pal","year":"2018","unstructured":"Pal, S. K. et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 8, 812\u2013821 (2018).","journal-title":"Cancer Discov."},{"key":"2934_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","volume":"11","author":"IM Silverman","year":"2021","unstructured":"Silverman, I. M. et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 11, 326\u2013339 (2021).","journal-title":"Cancer Discov."},{"key":"2934_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","volume":"14","author":"S Yue","year":"2021","unstructured":"Yue, S. et al. FGFR-TKI resistance in cancer: current status and perspectives. J. Hematol. Oncol. 14, 23 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2934_CR28","doi-asserted-by":"crossref","unstructured":"Necchi, A. et al. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF\/FGFR genomic alterations: final results from FIGHT-201. Ann. Oncol. 35, 200\u2013210 (2024).","DOI":"10.1016\/j.annonc.2023.10.794"},{"key":"2934_CR29","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1200\/JCO.19.02630","volume":"38","author":"YK Chae","year":"2020","unstructured":"Chae, Y. K. et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W. J. Clin. Oncol. 38, 2407\u20132417 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2934_CR30","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/bjc.2017.330","volume":"117","author":"KP Papadopoulos","year":"2017","unstructured":"Papadopoulos, K. P. et al. A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br. J. Cancer 117, 1592\u20131599 (2017).","journal-title":"Br. J. Cancer"},{"key":"2934_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"2934_CR32","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","volume":"11","author":"JM Cleary","year":"2021","unstructured":"Cleary, J. M. et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 11, 2488\u20132505 (2021).","journal-title":"Cancer Discov."},{"key":"2934_CR33","doi-asserted-by":"publisher","first-page":"102170","DOI":"10.1016\/j.ctrv.2021.102170","volume":"95","author":"L Goyal","year":"2021","unstructured":"Goyal, L., Kongpetch, S., Crolley, V. E. & Bridgewater, J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat. Rev. 95, 102170 (2021).","journal-title":"Cancer Treat. Rev."},{"key":"2934_CR34","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","volume":"19","author":"MA Krook","year":"2020","unstructured":"Krook, M. A. et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol. Cancer Ther. 19, 847\u2013857 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2934_CR35","doi-asserted-by":"publisher","first-page":"a004002","DOI":"10.1101\/mcs.a004002","volume":"5","author":"MA Krook","year":"2019","unstructured":"Krook, M. A. et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb. Mol. Case Study 5, a004002 (2019).","journal-title":"Cold Spring Harb. Mol. Case Study"},{"key":"2934_CR36","first-page":"PO.20.00178","volume":"5","author":"AM Varghese","year":"2021","unstructured":"Varghese, A. M. et al. Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. JCO Precis. Oncol. 5, PO.20.00178 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"2934_CR37","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","volume":"28","author":"AB Lassman","year":"2022","unstructured":"Lassman, A. B. et al. Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study. Clin. Cancer Res. 28, 2270\u20132277 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2934_CR38","first-page":"PO.21.00064","volume":"5","author":"JJ Gile","year":"2021","unstructured":"Gile, J. J. et al. FGFR inhibitor toxicity and efficacy in cholangiocarcinoma: multicenter single-institution cohort experience. JCO Precis. Oncol. 5, PO.21.00064 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"2934_CR39","first-page":"PO.20.00444","volume":"5","author":"S Farouk Sait","year":"2021","unstructured":"Farouk Sait, S. et al. Debio1347, an oral FGFR inhibitor: results from a single-center study in pediatric patients with recurrent or refractory FGFR-altered gliomas. JCO Precis. Oncol. 5, PO.20.00444 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"2934_CR40","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","volume":"29","author":"BJ Guercio","year":"2023","unstructured":"Guercio, B. J. et al. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin. Cancer Res. 29, 4586\u20134595 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2934_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00510","volume":"6","author":"K Mody","year":"2022","unstructured":"Mody, K. et al. Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. JCO Precis. Oncol. 6, e2100510 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"2934_CR42","doi-asserted-by":"publisher","first-page":"430","DOI":"10.6004\/jnccn.2021.7121","volume":"20","author":"AK Rengan","year":"2022","unstructured":"Rengan, A. K. & Denlinger, C. S. Robust response to futibatinib in a patient with metastatic FGFR-addicted cholangiocarcinoma previously treated using pemigatinib. J. Natl Compr. Cancer Netw. 20, 430\u2013435 (2022).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"2934_CR43","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","volume":"9","author":"L Goyal","year":"2019","unstructured":"Goyal, L. et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 9, 1064\u20131079 (2019).","journal-title":"Cancer Discov."},{"key":"2934_CR44","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/JCO.2023.41.4_suppl.539","volume":"41","author":"MM Javle","year":"2023","unstructured":"Javle, M. M. et al. Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: interim analysis. J. Clin. Oncol. 41, 539\u2013539 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2934_CR45","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"2934_CR46","doi-asserted-by":"publisher","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Prec. Oncol. https:\/\/doi.org\/10.1200\/po.17.00011 (2017).","DOI":"10.1200\/po.17.00011"},{"key":"2934_CR47","unstructured":"An Online Catalog of Human Genes and Genetic Disorders (OMIM, 2024); https:\/\/omim.org\/"},{"key":"2934_CR48","unstructured":"FoundationOne CDx. Technical Information (Foundation Medicine, 2023)."},{"key":"2934_CR49","unstructured":"Predicine Inc. PredicineCARE (Predicine, 2023)."}],"updated-by":[{"DOI":"10.1038\/s41591-024-03072-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02934-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T10:11:37Z","timestamp":1718791897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02934-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2934"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-02934-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-03072-w","URL":"https:\/\/doi.org\/10.1038\/s41591-024-03072-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R. served as a consultant or advisor for AADi, Avoro Capital Advisors, Boxer Capital, Chinese University of Hong Kong, Clarion Healthcare, Columbus Venture Partners, Cullgen, Debiopharm Group, Ellipses Pharma, Envision Pharma Group, Incyte, iOnctura, Macrogenics, Merus, Monte Rosa Therapeutics, Oncology One, Pfizer, Sardona Therapeutics, Vall d\u2019Hebron Institute of Oncology\/Ministerio de Empleo y Seguridad Social and Tang Advisors; received travel support from ESMO; received research funding paid directly to the institution from AADi, Amgen, Bayer, Bicycle Therapeutics, BioAtla, BioMed Valley Discoveries, Black Diamond Therapeutics, Blueprint Medicines, Cellestia Biotech, Curis, CytomX Therapeutics, Deciphera, Fore Biotherapeutics, Genmab, GlaxoSmithKline, Hummingbird, Hutchison MediPharma, IDEAYA Biosciences, Incyte, Kelun, Linnaeus Therapeutics, Loxo, Merck Sharp & Dohme, Merus, Mirati Therapeutics, Novartis, Nuvation Bio, Pfizer, Roche, Spectrum Pharmaceuticals, Symphogen, Taiho Pharmaceutical, Takeda\/Millennium, Tango Therapeutics, Vall d\u2019Hebron Institute of Oncology\/Cancer Core Europe and Yingli Pharma; and reported a relationship with Vall d\u2019Hebron Institute of Oncology\/Ministerio de Empleo y Seguridad Social. S.D. received research funding paid directly to the institution from Basilea Pharmaceutica, Incyte, Nerviano Medical Science, Pfizer and Roche. M.F. received institutional research grants from AbbVie, Amgen, Aprea, AstraZeneca, Beigene, BMS, Checkmate, Elicio, Genmab, Gilead, GSK, Incyte, Jacobio, Lilly, Merck, Mirati and Novartis; served on advisory boards for AbbVie, AstraZeneca, Jazz Pharma, Beigene and Mirati; and is a consultant for Omega Therapeutics and Novartis. J.G.-D. received research funding from Astellas, BMS, GSK, Ipsen, Janssen, Pfizer, Roche and Sanofi and honoraria for serving as a speaker for AstraZeneca, BMS, Janssen and Roche. A.I. served on advisory boards for AstraZeneca, Bayer, Chugai, Daiichi Sankyo, GSK, Merck, MSD, Parthenon and Roche and received research grants from AstraZeneca, Bayer, BMS, GSK, Merck, MSD, Novartis, Parthenon, Pfizer and Roche. I.S. received institutional research grants from Alligator Bioscience, AstraZeneca, BMS, Cantargia AB, Genentech, Genmab, Incyte, Loxo\/Bayer, Loxo\/Lilly, MSD, Novartis, Orion, Roche, Pfizer, Puma Biotechnology and Symphogen and support for attending meetings and\/or travel expenses from AstraZeneca, Incyte, Merck and Pfizer. M.U. received research grants from Astellas Pharma, AstraZeneca, Boehringer Ingelheim, CHUGAI Pharmaceutical, DFP, Eisai, Eli Lilly, Incyte, J-Pharma, Merck Biopharma, MSD, Novartis, Ono Pharmaceutical and Taiho Pharmaceutical and honoraria from AstraZeneca, CHUGAI Pharmaceutical, Eisai, Incyte, MSD, Novartis, Ono Pharmaceutical and Taiho Pharmaceutical. T.Y. received research grants from AbbVie, AMED, Ascent, AstraZeneca, GlaxoSmithKlineINBC, Incyte, Lilly, Merck Biopharma, MSD, Nanobiotix, Novartis, Ono Pharmaceutical, Pfizer, Roche and Syneos Health and lecture fees from AstraZeneca, Bristol-Meyers Squibb, Chugai, Eisai, Merck Biopharma, MSD, Ono Pharmaceutical and Rakuten Medical. M.L.V., N.O., X.L., A.G. and M.S. are employees and shareholders of Incyte. L.G. served on a data safety and monitoring committee for AstraZeneca and on advisory boards or as a consultant for Alentis Therapeutics AG, Black Diamond, Blueprint Medicine, Compass Therapeutics, Eisai\/H3Biomedicine, Exelixis, Genentech, Kinnate, Incyte Corporation, Merck, QED Therapeutics, Servier, Sirtex Medical, Surface Oncology, Taiho Oncology, TranstheraBio, Tyra Biosciences, AbbVie, AstraZeneca and Cogent Biosciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}